Literature DB >> 31413807

Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody-Drug Conjugates (ADCs).

Katie E Archer1, Emily E Reid1, Manami Shizuka1, James Woods1, Luke Harris1, Erin K Maloney1, Laura M Bartle1, Olga Ab1, Alan Wilhelm1, Yulius Setiady1, Jose F Ponte1, Rajeeva Singh1, Thomas A Keating1, Ravi V J Chari1, Michael L Miller1.   

Abstract

Indolinobenzodiazepine DNA alkylators (IGNs) are the cytotoxic payloads in antibody-drug conjugates (ADCs) currently undergoing Phase I clinical evaluation (IMGN779, IMGN632, and TAK164). These ADCs possess linkers that have been incorporated into a central substituted phenyl spacer. Here, we present an alternative strategy for the IGNs, linking through a carbamate at the readily available N-10 amine present in the monoimine containing dimer. As a result, we have designed a series of N-10 linked IGN ADCs with a wide range of in vitro potency and tolerability, which may allow us to better match an IGN with a particular target based on the potential dosing needs.

Entities:  

Year:  2019        PMID: 31413807      PMCID: PMC6691681          DOI: 10.1021/acsmedchemlett.9b00254

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  16 in total

1.  Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers.

Authors:  Stephen J Gregson; Philip W Howard; Darren R Gullick; Anzu Hamaguchi; Kathryn E Corcoran; Natalie A Brooks; John A Hartley; Terence C Jenkins; Sejal Patel; Matthew J Guille; David E Thurston
Journal:  J Med Chem       Date:  2004-02-26       Impact factor: 7.446

Review 2.  Antibody Drug Conjugates for Cancer Therapy.

Authors:  Paul Polakis
Journal:  Pharmacol Rev       Date:  2016-01       Impact factor: 25.468

3.  Expanding the Reach of Antibody-Drug Conjugates.

Authors:  Ravi V J Chari
Journal:  ACS Med Chem Lett       Date:  2016-09-15       Impact factor: 4.345

Review 4.  Antibody-drug conjugates: an emerging concept in cancer therapy.

Authors:  Ravi V J Chari; Michael L Miller; Wayne C Widdison
Journal:  Angew Chem Int Ed Engl       Date:  2014-02-20       Impact factor: 15.336

Review 5.  Antibody-drug conjugates in cancer therapy.

Authors:  Eric L Sievers; Peter D Senter
Journal:  Annu Rev Med       Date:  2012-10-03       Impact factor: 13.739

6.  SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.

Authors:  John A Hartley; Victoria J Spanswick; Natalie Brooks; Peter H Clingen; Peter J McHugh; Daniel Hochhauser; R Barbara Pedley; Lloyd R Kelland; Michael C Alley; Robert Schultz; Melinda G Hollingshead; Karen M Schweikart; Joseph E Tomaszewski; Edward A Sausville; Stephen J Gregson; Philip W Howard; David E Thurston
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

7.  DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.

Authors:  Yusuke Ogitani; Tetsuo Aida; Katsunobu Hagihara; Junko Yamaguchi; Chiaki Ishii; Naoya Harada; Masako Soma; Hiromi Okamoto; Masataka Oitate; Shingo Arakawa; Takehiro Hirai; Ryo Atsumi; Takashi Nakada; Ichiro Hayakawa; Yuki Abe; Toshinori Agatsuma
Journal:  Clin Cancer Res       Date:  2016-03-29       Impact factor: 12.531

8.  A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity.

Authors:  Michael L Miller; Nathan E Fishkin; Wei Li; Kathleen R Whiteman; Yelena Kovtun; Emily E Reid; Katie E Archer; Erin K Maloney; Charlene A Audette; Michele F Mayo; Alan Wilhelm; Holly A Modafferi; Rajeeva Singh; Jan Pinkas; Victor Goldmacher; John M Lambert; Ravi V J Chari
Journal:  Mol Cancer Ther       Date:  2016-05-23       Impact factor: 6.261

9.  Effect of base sequence on the DNA cross-linking properties of pyrrolobenzodiazepine (PBD) dimers.

Authors:  Khondaker M Rahman; Colin H James; David E Thurston
Journal:  Nucleic Acids Res       Date:  2011-03-21       Impact factor: 16.971

Review 10.  From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs).

Authors:  Julia Mantaj; Paul J M Jackson; Khondaker M Rahman; David E Thurston
Journal:  Angew Chem Int Ed Engl       Date:  2016-11-15       Impact factor: 15.336

View more
  3 in total

Review 1.  CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Authors:  Elodie Bôle-Richard; Naveen Pemmaraju; Blandine Caël; Etienne Daguindau; Andrew A Lane
Journal:  Cancers (Basel)       Date:  2022-05-03       Impact factor: 6.575

2.  Visible-light enabled room-temperature dealkylative imidation of secondary and tertiary amines promoted by aerobic ruthenium catalysis.

Authors:  Dong Yang; Jingqi Shi; Jiaming Chen; Xiaoqi Jia; Cuiying Shi; Lifang Ma; Ziyuan Li
Journal:  RSC Adv       Date:  2021-05-25       Impact factor: 4.036

Review 3.  The Chemistry Behind ADCs.

Authors:  Vesela Kostova; Patrice Désos; Jérôme-Benoît Starck; Andras Kotschy
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.